骨髓瘤的免疫微环境
The immune microenvironment of myeloma.
作者信息
Noonan Kimberly, Borrello Ivan
机构信息
Department of Oncology, Johns Hopkins University, 1650 Orleans St CRB-1, Rm 453, Baltimore, MD, 21231, USA.
出版信息
Cancer Microenviron. 2011 Dec;4(3):313-23. doi: 10.1007/s12307-011-0086-3. Epub 2011 Aug 25.
Abstract
The bone marrow (BM) is the site of disease in myeloma and possesses unique immune characteristics involved in the pathobiology of the disease. Interactions of plasma cells with stromal cells, osteoclasts, osteoblasts, myeloid and lymphoid cells make up the unique bone marrow milieu that mediates myeloma disease progression. Independently or through a complex network of interactions these cells impart immune changes leading to immune evasion and disease progression. The critical role of these factors in disease progression has led to the intense development of therapeutic strategies aimed at either disrupting the immune mechanisms mediating disease progression or augmenting those with anti-tumor benefits. This review discusses the major contributors of immunity in the bone marrow microenvironment, their interactions, and mechanisms whereby immune modulation can be translated into therapies with anti-myeloma efficacy.
摘要
骨髓（BM）是骨髓瘤的病变部位，具有参与该疾病病理生物学过程的独特免疫特征。浆细胞与基质细胞、破骨细胞、成骨细胞、髓系细胞和淋巴细胞之间的相互作用构成了介导骨髓瘤疾病进展的独特骨髓微环境。这些细胞独立地或通过复杂的相互作用网络引发免疫变化，导致免疫逃逸和疾病进展。这些因素在疾病进展中的关键作用促使人们大力开发治疗策略，旨在破坏介导疾病进展的免疫机制或增强具有抗肿瘤益处的免疫机制。本文综述讨论了骨髓微环境中免疫的主要贡献者、它们之间的相互作用，以及免疫调节可转化为具有抗骨髓瘤疗效的治疗方法的机制。
相似文献
1
The immune microenvironment of myeloma.骨髓瘤的免疫微环境
Cancer Microenviron. 2011 Dec;4(3):313-23. doi: 10.1007/s12307-011-0086-3. Epub 2011 Aug 25.
2
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression.肿瘤微环境在多发性骨髓瘤发生发展中的作用
Cancers (Basel). 2021 Jan 9;13(2):217. doi: 10.3390/cancers13020217.
3
Role of Immune Cells and Immunotherapy in Multiple Myeloma.免疫细胞与免疫疗法在多发性骨髓瘤中的作用
Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461.
4
The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.骨髓微环境在多发性骨髓瘤中恶性浆细胞生长和发育中的作用。
Int J Mol Sci. 2021 Apr 24;22(9):4462. doi: 10.3390/ijms22094462.
5
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance.骨髓微环境在多发性骨髓瘤进展和治疗耐药中的作用。
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e752-e768. doi: 10.1016/j.clml.2020.05.026. Epub 2020 Jun 7.
6
Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.靶向多发性骨髓瘤细胞与骨髓瘤骨髓微环境的相互作用。
Int J Hematol. 2011 Oct;94(4):334-343. doi: 10.1007/s12185-011-0949-x. Epub 2011 Oct 18.
7
The Immune Microenvironment in Multiple Myeloma: Friend or Foe?多发性骨髓瘤中的免疫微环境：朋友还是敌人？
Cancers (Basel). 2021 Feb 5;13(4):625. doi: 10.3390/cancers13040625.
8
The impact of the bone marrow microenvironment on multiple myeloma (Review).骨髓微环境对多发性骨髓瘤的影响（综述）
Oncol Rep. 2019 Oct;42(4):1272-1282. doi: 10.3892/or.2019.7261. Epub 2019 Aug 5.
9
Bone marrow microenvironment in multiple myeloma progression.多发性骨髓瘤进展中的骨髓微环境
J Biomed Biotechnol. 2012;2012:157496. doi: 10.1155/2012/157496. Epub 2012 Oct 3.
10
Tumor-host cell interactions in the bone disease of myeloma.骨髓瘤骨病中的肿瘤-宿主细胞相互作用。
Bone. 2011 Jan;48(1):121-8. doi: 10.1016/j.bone.2010.06.029. Epub 2010 Jul 13.
引用本文的文献
1
Biphasic behavior of T cell subsets reflects failure of early anti-myeloma response and leads to progressive T cell dysfunction.T细胞亚群的双相行为反映了早期抗骨髓瘤反应的失败，并导致进行性T细胞功能障碍。
Neoplasia. 2025 Sep;67:101208. doi: 10.1016/j.neo.2025.101208. Epub 2025 Jul 11.
2
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.新诊断的不符合移植条件的多发性骨髓瘤患者免疫不全的恢复情况，这是一个补充微小残留病的独立预后因素。
Ann Hematol. 2024 Dec;103(12):5651-5661. doi: 10.1007/s00277-024-06031-0. Epub 2024 Oct 23.
3
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.一项单细胞图谱描绘了与多发性骨髓瘤预后相关的骨髓免疫微环境失调情况。
bioRxiv. 2024 May 17:2024.05.15.593193. doi: 10.1101/2024.05.15.593193.
4
Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.系统评价和荟萃分析：多发性骨髓瘤患者对 COVID-19 疫苗接种的免疫反应。
BMC Geriatr. 2024 May 8;24(1):411. doi: 10.1186/s12877-024-05006-0.
5
Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data.通过对基因表达综合数据库（GEO）数据的荟萃分析，对意义未明的单克隆丙种球蛋白病进展为多发性骨髓瘤进行特征分析。
Heliyon. 2023 Jun 28;9(7):e17298. doi: 10.1016/j.heliyon.2023.e17298. eCollection 2023 Jul.
6
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma.快速进展性多发性骨髓瘤免疫微环境的跨中心单细胞RNA测序研究
NPJ Genom Med. 2023 Jan 26;8(1):3. doi: 10.1038/s41525-022-00340-x.
7
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.用新型聚合物偶联人白细胞介素-15（NKTR-255）改善多发性骨髓瘤患者的自然杀伤细胞功能。
Blood Adv. 2023 Jan 10;7(1):9-19. doi: 10.1182/bloodadvances.2022007985.
8
Reply to Comment on "In vivo flow cytometry reveals a circadian rhythm of circulating tumor cells".对《体内流式细胞术揭示循环肿瘤细胞的昼夜节律》评论的回复
Light Sci Appl. 2021 Sep 17;10(1):189. doi: 10.1038/s41377-021-00625-3.
9
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis.环磷酰胺通过增强巨噬细胞介导的抗体依赖性细胞吞噬作用来改变肿瘤细胞分泌组，从而增强达雷妥尤单抗的抗骨髓瘤活性。
Oncoimmunology. 2021 Jan 25;10(1):1859263. doi: 10.1080/2162402X.2020.1859263.
10
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling.癌症相关血管生成：作为免疫巡逻检查点的内皮细胞
Cancers (Basel). 2020 Nov 15;12(11):3380. doi: 10.3390/cancers12113380.
本文引用的文献
1
Lenalidomide - current understanding of mechanistic properties.来那度胺-对作用机制特性的现有认识。
Anticancer Agents Med Chem. 2011 Mar;11(3):315-26. doi: 10.2174/187152011795347487.
2
From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.从骨髓瘤前体疾病到多发性骨髓瘤：新的诊断概念和早期干预机会。
Clin Cancer Res. 2011 Mar 15;17(6):1243-52. doi: 10.1158/1078-0432.CCR-10-1822.
3
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.随机、双盲研究地舒单抗与唑来膦酸治疗晚期癌症（不包括乳腺癌和前列腺癌）或多发性骨髓瘤患者的骨转移。
J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.
4
New immunomodulatory drugs in myeloma.骨髓瘤的新型免疫调节药物。
Curr Hematol Malig Rep. 2011 Jun;6(2):120-5. doi: 10.1007/s11899-011-0077-y.
5
NK cells and immune "memory".自然杀伤细胞与免疫“记忆”。
J Immunol. 2011 Feb 15;186(4):1891-7. doi: 10.4049/jimmunol.1003035.
6
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.通过将 IL-12 表达靶向和控制到肿瘤微环境中来改善过继性 T 细胞疗法。
Mol Ther. 2011 Apr;19(4):751-9. doi: 10.1038/mt.2010.313. Epub 2011 Feb 1.
7
Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.循证迷你综述：既往接受新型药物和大剂量化疗及自体造血干细胞移植治疗的复发/难治性骨髓瘤患者的治疗选择。
Hematology Am Soc Hematol Educ Program. 2010;2010:310-3. doi: 10.1182/asheducation-2010.1.310.
8
Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.利用自然杀伤 T（NKT）细胞治疗人类骨髓瘤：进展与挑战。
Clin Immunol. 2011 Aug;140(2):160-6. doi: 10.1016/j.clim.2010.12.010. Epub 2011 Jan 12.
9
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.嵌合型 NKG2D 受体表达 T 细胞过继转移治疗多发性骨髓瘤。
Gene Ther. 2011 May;18(5):509-16. doi: 10.1038/gt.2010.174. Epub 2011 Jan 6.
10
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.达雷妥尤单抗，一种新型治疗性人源 CD38 单克隆抗体，可诱导多发性骨髓瘤和其他血液系统肿瘤的杀伤。
J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.
Zotero 插件